Read the latest from Baszucki Group and its partners.
July 21, 2022 — The Baszuckis are showing how philanthropy, even one organization, can potentially make a big impact on an underfunded field of research. But they can’t solve this on their own — by getting this new research rolling, their most significant role could be producing promising results that attract new funders to the space.
July 18, 2022 — The Baszucki Brain Research Fund is pleased to announce that five science teams around the globe have received funding to study ketogenic metabolic interventions for bipolar disorder, schizophrenia and major depressive disorder.
July 7, 2022 — This 5-minute NBC segment showcases another promising area the Baszuckis have invested in: a more targeted approach to Transcranial Magnetic Stimulation (TMS), facilitated by Magnus Medical. The company was able to end their FDA study early because the results were so impactful — 80% of depressed patients went into remission.
May 3, 2022 — During an appearance at the annual Milken Institute Global Conference, David Baszucki explained why he and his family decided to direct a portion of their philanthropy to mental health research.